share_log

Bellerophon Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(12.1%),Janus Henderson Biotech Innovation Master Fund Ltd(10.4%)

Bellerophon Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Janus Henderson Group plc(12.1%),Janus Henderson Biotech Innovation Master Fund Ltd(10.4%)

SEC announcement ·  2023/05/26 16:41
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息